Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Study Summary

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Conditions

Non-Small Cell Lung Cancer

Interventions / Drugs

Datopotamab Deruxtecan Rilvegostomig Pembrolizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment675 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.910956+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.